Intervention

Trastuzumab SC

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting1

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

ATEMPT 2.0: Adjuvant T-DM1 vs THNCT04893109 · 2021-06-16

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerNCT03493854 · 2018-06-14

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsNCT03144947 · 2016-11-29

Common conditions

Breast Cancer1 Cancer, Breast1 Early Breast Cancer1 HER2-positive Breast Cancer1

Leading sponsors

Dana-Farber Cancer Institute1 Gruppo Oncologico Italiano di Ricerca Clinica1 Hoffmann-La Roche1

Trial status mix

COMPLETED1

RECRUITING1

UNKNOWN1

Phase mix

PHASE22

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.